Cytokinetics Announces Upcoming Presentations at HCMS Scientific Sessions and HFSA Annual Scientific Meeting Page 1

Analyses of the effects of Aficamten on key clinical outcomes in SEQUOIA-HCM are presented in a recent presentation from a clinical trial in HFSA

SOUTH SAN FRANCISCO, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three presentations at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions on September 27, 2024, and one presentation on a Late Breaking Clinical Trial at the Heart Failure Society of America (HFSA) Annual Scientific Meeting, taking place September 27-30, 2024, both in Atlanta, GA.